JP2013521231A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013521231A5 JP2013521231A5 JP2012555195A JP2012555195A JP2013521231A5 JP 2013521231 A5 JP2013521231 A5 JP 2013521231A5 JP 2012555195 A JP2012555195 A JP 2012555195A JP 2012555195 A JP2012555195 A JP 2012555195A JP 2013521231 A5 JP2013521231 A5 JP 2013521231A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- medicament
- skeletal muscle
- induced
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims 11
- 238000005399 mechanical ventilation Methods 0.000 claims 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims 7
- 210000003205 muscle Anatomy 0.000 claims 5
- 108090000623 proteins and genes Proteins 0.000 claims 5
- 238000011282 treatment Methods 0.000 claims 5
- 238000001990 intravenous administration Methods 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 210000002027 skeletal muscle Anatomy 0.000 claims 4
- 238000007920 subcutaneous administration Methods 0.000 claims 4
- 230000009885 systemic effect Effects 0.000 claims 4
- 230000000699 topical effect Effects 0.000 claims 4
- 208000026214 Skeletal muscle atrophy Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 230000004064 dysfunction Effects 0.000 claims 3
- 238000007918 intramuscular administration Methods 0.000 claims 3
- 238000007912 intraperitoneal administration Methods 0.000 claims 3
- 230000004792 oxidative damage Effects 0.000 claims 3
- 230000025185 skeletal muscle atrophy Effects 0.000 claims 3
- 238000007910 systemic administration Methods 0.000 claims 3
- 238000011200 topical administration Methods 0.000 claims 3
- 102100040669 F-box only protein 32 Human genes 0.000 claims 2
- 101710191029 F-box only protein 32 Proteins 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 239000000090 biomarker Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 208000013363 skeletal muscle disease Diseases 0.000 claims 2
- 102000007590 Calpain Human genes 0.000 claims 1
- 108010032088 Calpain Proteins 0.000 claims 1
- 102000003952 Caspase 3 Human genes 0.000 claims 1
- 108090000397 Caspase 3 Proteins 0.000 claims 1
- 102000004066 Caspase-12 Human genes 0.000 claims 1
- 108090000570 Caspase-12 Proteins 0.000 claims 1
- 102100025014 E3 ubiquitin-protein ligase TRIM63 Human genes 0.000 claims 1
- 101710164910 E3 ubiquitin-protein ligase TRIM63 Proteins 0.000 claims 1
- 101710145505 Fiber protein Proteins 0.000 claims 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 claims 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 claims 1
- 102100031874 Spectrin alpha chain, non-erythrocytic 1 Human genes 0.000 claims 1
- 101710157175 Spectrin alpha chain, non-erythrocytic 1 Proteins 0.000 claims 1
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 claims 1
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 claims 1
- 230000001086 cytosolic effect Effects 0.000 claims 1
- 238000006731 degradation reaction Methods 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 210000001087 myotubule Anatomy 0.000 claims 1
- 230000001590 oxidative effect Effects 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 210000002235 sarcomere Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30850810P | 2010-02-26 | 2010-02-26 | |
| US61/308,508 | 2010-02-26 | ||
| PCT/US2011/026339 WO2011106717A1 (en) | 2010-02-26 | 2011-02-25 | Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016110116A Division JP2016164194A (ja) | 2010-02-26 | 2016-06-01 | ミトコンドリア標的化抗酸化剤は機械的人工呼吸誘発性横隔膜機能障害および骨格筋萎縮を防止する |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013521231A JP2013521231A (ja) | 2013-06-10 |
| JP2013521231A5 true JP2013521231A5 (enExample) | 2014-04-17 |
Family
ID=44507242
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012555195A Pending JP2013521231A (ja) | 2010-02-26 | 2011-02-25 | ミトコンドリア標的化抗酸化剤は機械的人工呼吸誘発性横隔膜機能障害および骨格筋萎縮を防止する |
| JP2016110116A Pending JP2016164194A (ja) | 2010-02-26 | 2016-06-01 | ミトコンドリア標的化抗酸化剤は機械的人工呼吸誘発性横隔膜機能障害および骨格筋萎縮を防止する |
| JP2017182579A Pending JP2017226699A (ja) | 2010-02-26 | 2017-09-22 | ミトコンドリア標的化抗酸化剤は機械的人工呼吸誘発性横隔膜機能障害および骨格筋萎縮を防止する |
| JP2018242635A Pending JP2019069985A (ja) | 2010-02-26 | 2018-12-26 | ミトコンドリア標的化抗酸化剤は機械的人工呼吸誘発性横隔膜機能障害および骨格筋萎縮を防止する |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016110116A Pending JP2016164194A (ja) | 2010-02-26 | 2016-06-01 | ミトコンドリア標的化抗酸化剤は機械的人工呼吸誘発性横隔膜機能障害および骨格筋萎縮を防止する |
| JP2017182579A Pending JP2017226699A (ja) | 2010-02-26 | 2017-09-22 | ミトコンドリア標的化抗酸化剤は機械的人工呼吸誘発性横隔膜機能障害および骨格筋萎縮を防止する |
| JP2018242635A Pending JP2019069985A (ja) | 2010-02-26 | 2018-12-26 | ミトコンドリア標的化抗酸化剤は機械的人工呼吸誘発性横隔膜機能障害および骨格筋萎縮を防止する |
Country Status (6)
| Country | Link |
|---|---|
| US (6) | US20130040901A1 (enExample) |
| EP (4) | EP3167896A1 (enExample) |
| JP (4) | JP2013521231A (enExample) |
| CN (2) | CN102834105A (enExample) |
| CA (1) | CA2790823A1 (enExample) |
| WO (1) | WO2011106717A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3150215A1 (en) | 2009-08-24 | 2017-04-05 | Stealth Peptides International, Inc. | Methods and compositions for preventing or treating opthalmic conditions |
| EP3560508A1 (en) * | 2010-03-15 | 2019-10-30 | Stealth Peptides International, Inc. | Combination therapies using cyclosporine and aromatic cationic peptides |
| EP2788013A4 (en) * | 2011-12-09 | 2015-08-19 | Stealth Peptides Int Inc | AROMATIC-CATIONIC PEPTIDES AND USES THEREOF |
| EP3170506B1 (en) | 2012-03-30 | 2018-05-16 | Stealth Peptides International, Inc. | Methods and compositions for the prevention and treatment neuropathy |
| CN104661670A (zh) * | 2012-08-02 | 2015-05-27 | 康肽德生物医药技术有限公司 | 用于治疗动脉粥样硬化的方法 |
| MX2015005102A (es) * | 2012-10-22 | 2016-02-09 | Stealth Peptides Int Inc | Metodos para la reduccion de los riesgos asociados con el insuficiencia cardiaca y factores asociado con el mismo. |
| CN115990242A (zh) | 2013-03-01 | 2023-04-21 | 康德生物医疗有限公司 | 预防或治疗巴斯综合征的方法和组合物 |
| CN117752766A (zh) * | 2013-03-01 | 2024-03-26 | 康德生物医疗有限公司 | 治疗线粒体疾病的方法 |
| WO2014209905A2 (en) | 2013-06-26 | 2014-12-31 | Stealth Peptides International, Inc. | Methods and compositions for detecting and diagnosing diseases and conditions |
| CA2916492A1 (en) * | 2013-06-27 | 2014-12-31 | Stealth Biotherapeutics Corp | Peptide therapeutics and methods for using same |
| EP3182989B1 (en) * | 2014-08-21 | 2021-04-14 | Stealth Biotherapeutics Corp | Peptide d-arg-2',6'-dmt-lys-phe-nh2 for treating alport syndrome |
| WO2016144968A1 (en) * | 2015-03-09 | 2016-09-15 | University Of Washington | Relaxin therapy for disorders of the diaphragm |
| EP4233887A1 (en) * | 2016-01-06 | 2023-08-30 | Stealth BioTherapeutics Inc. | Methods for the treatment of duchenne muscular dystrophy |
| AU2017249218B2 (en) | 2016-04-11 | 2020-08-27 | Arcuate Therapeutics, Inc. | Chiral peptides |
| EP4000690A1 (en) * | 2016-05-19 | 2022-05-25 | Stealth BioTherapeutics Inc. | Compositions and methods for the prevention and treatment of mitochondrial myopathies |
| US10398732B2 (en) | 2016-10-13 | 2019-09-03 | Marshall University Research Corporation | Compositions and methods for treating striated muscle injury, treating striated muscle atrophy and/or for promoting striated muscle growth |
| KR101986882B1 (ko) * | 2017-01-06 | 2019-06-07 | 연세대학교 산학협력단 | 오시멘, 유게놀 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는 근육 질환 예방 또는 치료용 조성물 |
| JP2019099488A (ja) * | 2017-11-30 | 2019-06-24 | 小林製薬株式会社 | ペプチド及びその利用 |
| WO2022055811A1 (en) * | 2020-09-09 | 2022-03-17 | Social Profit Network | Methods and compositions for delivery of biotin to mitochondria |
| CN115400201A (zh) * | 2021-05-26 | 2022-11-29 | 四川大学华西医院 | Ss-31在制备预防和/或治疗香烟诱导的气道炎症及慢性阻塞性肺疾病的药物中的用途 |
| CN117881411A (zh) | 2021-06-01 | 2024-04-12 | 艾迪雅生物有限责任公司 | 用于眼部药物的延长释放药物递送系统和使用方法 |
| CN114870000B (zh) * | 2022-03-21 | 2025-10-28 | 中国人民解放军空军军医大学 | 用于线粒体靶向治疗的两亲性前药及其纳米颗粒的制备方法和应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5716644A (en) | 1992-06-11 | 1998-02-10 | Alkermes, Inc. | Composition for sustained release of non-aggregated erythropoietin |
| US5674534A (en) | 1992-06-11 | 1997-10-07 | Alkermes, Inc. | Composition for sustained release of non-aggregated erythropoietin |
| US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
| US6245740B1 (en) | 1998-12-23 | 2001-06-12 | Amgen Inc. | Polyol:oil suspensions for the sustained release of proteins |
| EP2865385B1 (en) * | 2003-02-04 | 2016-11-16 | Cornell Research Foundation, Inc. | Uses of aromatic-cationic peptide |
| CA2971928C (en) * | 2004-01-23 | 2019-01-08 | Cornell Research Foundation, Inc. | Methods for reducing oxidative damage |
| EP3563862B1 (en) * | 2009-03-20 | 2021-05-05 | The General Hospital Corporation d/b/a Massachusetts General Hospital | D-arg-2'6'-dimethyltyrosine-lys-phe-nh2 for use in the prevention of secondary complications of burn injuries |
| CN104725472A (zh) * | 2010-01-25 | 2015-06-24 | 康奈尔大学 | 芳香族阳离子肽及其用途 |
-
2011
- 2011-02-25 WO PCT/US2011/026339 patent/WO2011106717A1/en not_active Ceased
- 2011-02-25 EP EP16190808.2A patent/EP3167896A1/en not_active Withdrawn
- 2011-02-25 EP EP18211792.9A patent/EP3511012A1/en not_active Withdrawn
- 2011-02-25 JP JP2012555195A patent/JP2013521231A/ja active Pending
- 2011-02-25 EP EP17202437.4A patent/EP3332795A1/en not_active Withdrawn
- 2011-02-25 CN CN2011800185731A patent/CN102834105A/zh active Pending
- 2011-02-25 EP EP11748191.1A patent/EP2538958A4/en not_active Withdrawn
- 2011-02-25 CA CA2790823A patent/CA2790823A1/en not_active Abandoned
- 2011-02-25 US US13/580,237 patent/US20130040901A1/en not_active Abandoned
- 2011-02-25 CN CN201510229774.6A patent/CN104922653A/zh active Pending
-
2015
- 2015-04-03 US US14/678,535 patent/US20160058826A1/en not_active Abandoned
-
2016
- 2016-06-01 JP JP2016110116A patent/JP2016164194A/ja active Pending
- 2016-06-29 US US15/196,864 patent/US20170143784A1/en not_active Abandoned
-
2017
- 2017-09-22 JP JP2017182579A patent/JP2017226699A/ja active Pending
- 2017-12-04 US US15/830,496 patent/US20180311301A1/en not_active Abandoned
-
2018
- 2018-12-26 JP JP2018242635A patent/JP2019069985A/ja active Pending
-
2019
- 2019-10-07 US US16/595,223 patent/US20200282003A1/en not_active Abandoned
-
2022
- 2022-02-25 US US17/680,778 patent/US20230076067A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013521231A5 (enExample) | ||
| EA201270292A1 (ru) | Терапия глатирамером ацетатом с низкой кратностью | |
| US10517845B2 (en) | Compositions and methods for treating intestinal hyperpermeability | |
| KR20160093000A (ko) | 창자 과투과성을 치료하기 위한 티로신 하이드록실라제 억제제 | |
| RU2007125589A (ru) | Способ улучшения структуры и/или функций артериол, активный агент для улучшения структуры и/или функций артериол и набор для лечения состояний, характеризующихся ненормальной структурой или функцией артериол | |
| SG10201903512SA (en) | Bile Acid Recycling Inhibitors For Treatment Of Pediatric Cholestatic Liver Diseases | |
| JP2014528901A5 (enExample) | ||
| UA107578C2 (uk) | Комбінована терапія при лікуванні діабету | |
| JP2012530060A5 (enExample) | ||
| JP2012517478A5 (enExample) | ||
| WO2007149283A3 (en) | Use of kw-3902 for achieving diuresis in patients with congestive heart failure and acute fluid overload | |
| JP2012502909A5 (enExample) | ||
| ITUB20150635A1 (it) | Uso di un inibitore dell’aceticolinesterasi e composizioni farmaceutiche contenenti detto inibitore. | |
| CN107835695A (zh) | 用于治疗自闭症的组合物和方法 | |
| AU2020203316A1 (en) | Novel regimes of FXR agonists | |
| AU2017328999B2 (en) | Combination of FXR agonists | |
| CN108463221A (zh) | 吲哚类化合物刺激免疫系统的用途 | |
| JP2013523628A5 (enExample) | ||
| JP2016528171A5 (enExample) | ||
| JP2017508737A5 (enExample) | ||
| JP2015505314A5 (enExample) | ||
| JP2013523844A5 (enExample) | ||
| JP2014037445A (ja) | 抵抗性統合失調症およびその他のｃｎｓ疾患の治療 | |
| WO2007059211A3 (en) | Methods of treating fibrosing diseases by induction of immune tolerance | |
| PÉREZ et al. | Nebulized furosemide to treat breathlessness in emergency patients with advanced cancer |